New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - paclitaxel 100mg (nanoparticle albumin-bound);   - powder for injection - 100 mg - active: paclitaxel 100mg (nanoparticle albumin-bound)   excipient: albumin - abraxane is indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - levonorgestrel 0.75mg - tablet - 0.75 mg - active: levonorgestrel 0.75mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch povidone sunset yellow fcf - next choice is an oral emergency contraceptive indicated for use within 72 hours of unprotected intercourse. it should be used only as an emergency measure. women who present for repeated courses of emergency contraception should be advised to consider long-term methods of contraception.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - levonorgestrel 0.75mg - tablet - 750 mcg - active: levonorgestrel 0.75mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch povidone sunset yellow fcf - next choice is an oral emergency contraceptive indicated for use within 72 hours of unprotected intercourse. it should be used only as an emergency measure. women who present for repeated courses of emergency contraception should be advised to consider long-term methods of contraception.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - docetaxel 10 mg/ml - solution for infusion - 10 mg/ml - active: docetaxel 10 mg/ml excipient: citric acid ethanol macrogol 300 nitrogen as needed polysorbate 80 - treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. dbl docetaxel, concentrated injection in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. dbl™ docetaxel, concentrated injection in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - anastrozole 1mg - film coated tablet - 1 mg - active: anastrozole 1mg excipient: hypromellose lactose monohydrate magnesium stearate opadry white y-1-7000 povidone sodium starch glycolate - treatment of advanced breast cancer in post-menopausal women.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - irinotecan hydrochloride trihydrate 100mg; irinotecan hydrochloride trihydrate 100mg - concentrate for injection - 100 mg - active: irinotecan hydrochloride trihydrate 100mg excipient: lactic acid sodium hydroxide sorbitol water for injection active: irinotecan hydrochloride trihydrate 100mg excipient: hydrochloric acid lactic acid sodium hydroxide sorbitol water for injection - irinotecan actavis is indicated as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan actavis is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - irinotecan hydrochloride trihydrate 40mg; irinotecan hydrochloride trihydrate 40mg - concentrate for injection - 40 mg - active: irinotecan hydrochloride trihydrate 40mg excipient: lactic acid sodium hydroxide sorbitol water for injection active: irinotecan hydrochloride trihydrate 40mg excipient: hydrochloric acid lactic acid sodium hydroxide sorbitol water for injection - irinotecan actavis is indicated as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan actavis is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.